Chih-Chi Andrew Hu
Overview
Explore the profile of Chih-Chi Andrew Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi H, Wu Y, McDaniel Mims B, Pugel A, Tang C, Tian L, et al.
J Immunol
. 2024 Jun;
213(3):384-393.
PMID: 38864663
Allogeneic hematopoietic cell transplantation is an effective treatment for hematologic malignancies, but the complications such as graft-versus-host disease (GVHD) can limit its benefit. The conditioning regimens before transplant, including chemotherapy...
2.
Burns E, Wilson J, Mathur S, Kieser R, Gong Z, Hu C, et al.
Ann Hematol
. 2023 Jul;
102(10):2753-2763.
PMID: 37422592
Burkitt lymphoma (BL) is an extremely aggressive but curable subtype of non-Hodgkin lymphoma. While younger patients have excellent outcomes in response to aggressive chemoimmunotherapy, the rarity of this disease in...
3.
Ji Y, Luo Y, Wu Y, Sun Y, Zhao L, Xue Z, et al.
Nat Cell Biol
. 2023 May;
25(5):726-739.
PMID: 37142791
Stimulator of interferon genes (STING) orchestrates the production of proinflammatory cytokines in response to cytosolic double-stranded DNA; however, the pathophysiological significance and molecular mechanism underlying the folding and maturation of...
4.
Burns E, Gentille Sanchez C, Mathur S, Guerrero C, Muhsen I, Sarfraz H, et al.
Ann Hematol
. 2023 Mar;
102(5):1111-1120.
PMID: 36922432
Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-Hodgkin lymphoma that carries a poor prognosis in the elderly. The aim of this study is to investigate treatment...
5.
Lee A, Pingali S, Pinilla-Ibarz J, Atchison M, Koumenis C, Argon Y, et al.
Leukemia
. 2022 Aug;
36(10):2430-2442.
PMID: 36042317
Activation-induced cytidine deaminase (AID) has been implicated as both a positive and a negative factor in the progression of B cell chronic lymphocytic leukemia (CLL), but the role that it...
6.
Bagashev A, Sotillo E, Tang C, Black K, Perazzelli J, Seeholzer S, et al.
Mol Cell Biol
. 2022 Aug;
42(9):e0032822.
PMID: 35976030
No abstract available.
7.
Mogre S, Blazanin N, Walsh H, Ibinson J, Minnich C, Hu C, et al.
Mol Carcinog
. 2022 Aug;
61(10):958-971.
PMID: 35975910
Transforming Growth Factor β1 (TGFβ1) is a critical regulator of tumor progression in response to HRas. Recently, TGFβ1 has been shown to trigger ER stress in many disease models; however,...
8.
Shao A, Xu Q, Kang C, Cain C, Lee A, Tang C, et al.
Mol Pharm
. 2022 Mar;
19(4):1059-1067.
PMID: 35253431
Activation of the IRE-1/XBP-1s pathway supports tumor progression. Here, we report a novel prodrug, TC-D-F07, in which a thiol-reactive dinitrobenzenesulfonyl (Dns) cage was installed onto the C8 hydroxyl of the...
9.
Choi H, Tang C, Tian L, Wu Y, Sofi M, Ticer T, et al.
Front Immunol
. 2021 Oct;
12:705484.
PMID: 34659198
Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective therapeutic procedure to treat hematological malignancies. However, the benefit of allo-HCT is limited by a major complication, chronic graft-versus-host disease (cGVHD). Since...
10.
Zundell J, Fukumoto T, Lin J, Fatkhudinov N, Nacarelli T, Kossenkov A, et al.
Cancer Res
. 2021 Sep;
81(20):5325-5335.
PMID: 34548333
The SWI/SNF chromatin-remodeling complex is frequently altered in human cancers. For example, the SWI/SNF component is mutated in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective...